Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydronidone (F351) in HBV-induced Liver Fibrosis
NCT02499562Phase 2Completed
- Sponsor
- Shanghai Genomics
- Start
- Jun 2015
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydronidone in Liver Fibrosis (LF), sponsored by Shanghai Genomics. Started Jun 2015; status: completed.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT02499562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499562.